Soluble epoxide hydrolase inhibition alleviates chemotherapy induced neuropathic pain
Authors:
Open Access
- 9 January 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pain Research
- Vol. 3, 1100524
Abstract
Chemotherapy induced peripheral neuropathy (CIPN) is a particularly pernicious form of neuropathy and the associated pain is the primary dose-limiting factor of life-prolonging chemotherapy treatment. The prevalence of CIPN is high and can last long after treatment has been stopped. Currently, late in the COVID-19 pandemic, there are still increased psychological pressures on cancer patients as well as additional challenges in providing analgesia for them. These include the risks of nonsteroidal anti-inflammatory drug (NSAID) analgesics potentially masking early infection symptoms and the immunosuppression of steroidal and opiate based approaches. Even without these concerns, CIPN is often inadequately treated with few therapies that offer significant pain relief. The experiments we report use soluble epoxide hydrolase inhibitors (sEHI) which relieved this intractable pain in preclinical models. Doses of EC5026, an IND candidate intended to treat neuropathic pain, elicited dose dependent analgesic responses in multiple models including platinum-based, taxane, and vinca alkaloid-based CIPN pain in Sprague Dawley rats. At the same time as a class, the sEHI are known to result in fewer debilitating side effects of other analgesics, likely due to their novel mechanism of action. Overall, the observed dose-dependent analgesia in both male and female rats across multiple models of chemotherapy induced neuropathic pain holds promise as a useful tool when translated to the clinic.Keywords
This publication has 97 references indexed in Scilit:
- Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatinPain, 2012
- Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxelNeuroscience, 2012
- Synthesis and Structure−Activity Relationship Studies of Urea-Containing Pyrazoles as Dual Inhibitors of Cyclooxygenase-2 and Soluble Epoxide HydrolaseJournal of Medicinal Chemistry, 2011
- Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMPProceedings of the National Academy of Sciences, 2011
- Burden of chemotherapy-induced neuropathy—a cross-sectional studySupportive Care in Cancer, 2010
- Endoplasmic Reticulum Stress and the Inflammatory Basis of Metabolic DiseaseCell, 2010
- Protective actions of epoxyeicosatrienoic acid: Dual targeting of cardiovascular PI3K and KATP channelsJournal of Molecular and Cellular Cardiology, 2009
- Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-l-carnitine: Effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cellsExperimental Neurology, 2008
- Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitorsProceedings of the National Academy of Sciences, 2006
- Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitorsProceedings of the National Academy of Sciences, 2006